• GSK J4 HCl: JMJD3 Workflow Guide

  2026-08-22

  GSK J4 HCl enables cell-based testing of JMJD3-linked H3K27 demethylation in inflammatory, chromatin, and cancer workflows. This guide connects practical dosing, chromatin readouts, and troubleshooting to the CXCL10 methylation findings reported in human decidual models.

• Valemetostat in Reliable Cell Assays

  2026-08-21

  Learn how Valemetostat (DS-3201; SKU BA4816) can support better-controlled EZH2-focused cell viability and proliferation studies. This scenario-based guide covers formulation, dose interpretation, protocol handling, data comparison, and practical product selection.

• 3-Hydroxybutyrate (BHBA) in Ferroptosis Assays

  2026-08-20

  3-Hydroxybutyrate (BHBA) is both a ketone fuel and a signaling metabolite. This guide translates stroke research into a ferroptosis-aware assay framework that separates direct BHBA activity from whole-organism conditioning effects.

• Vancomycin hydrochloride in Resistance Workflows

  2026-08-20

  Vancomycin hydrochloride provides a mechanism-based Gram-positive control for susceptibility testing, resistance profiling, and Clostridium difficile infection studies. This guide combines practical reagent handling with a time-resolved modeling strategy inspired by recent resistance research.

• SGI-1027, DNMT1, and RB1 in Gastric Cancer

  2026-08-19

  A 2024 Discovery Medicine study links SGI-1027-mediated DNMT1 suppression with increased RB1 expression and reduced growth, migration, invasion, and metastasis of MKN45 gastric cancer cells. Its integrated cell and mouse experiments support a DNMT1–RB1 regulatory axis, while also highlighting the need for direct methylation and mechanistic validation.

• Catalpol and Cancer: Evidence, Mechanisms, and Limits

  2026-08-19

  This 2025 review synthesizes preclinical evidence that the iridoid glycoside catalpol can influence cancer-cell proliferation, apoptosis, metastasis, inflammation, oxidative stress, and angiogenesis across several tumor models. Its main value is mechanistic integration rather than clinical validation, because the underlying evidence remains limited to in vitro and animal studies.

• Ganetespib (STA-9090): Mechanism-to-Assay Guide

  2026-08-18

  Ganetespib (STA-9090) offers a powerful way to connect Hsp90 client-protein loss with cancer-cell phenotypes. This guide adds a compartment-resolved assay strategy inspired by new findings on NINJ1-dependent viral protein secretion, while clearly separating evidence from hypothesis.

• Decitabine: Reliable Cell Assay Design

  2026-08-18

  This scenario-based guide explains how Decitabine (5-Aza-2'-deoxycytidine), SKU A1906, can improve interpretation of viability, proliferation, and cytotoxicity assays. It connects dose selection, formulation, controls, and epigenetic readouts with product data and peer-reviewed toxicity evidence.

• EPZ-6438: A Practical EZH2 Inhibitor Workflow

  2026-08-17

  EPZ-6438 enables mechanism-led studies of PRC2 signaling, H3K27me3 loss, and cancer-cell response across cervical, lymphoma, and SMARCB1-deficient models. This guide combines compound handling, staged readouts, assay controls, and troubleshooting for more reproducible EZH2 inhibitor experiments.

• Cl-Amidine: PAD4 Assay Workflows

  2026-08-17

  Cl-Amidine enables researchers to isolate PAD4-dependent histone citrullination from broader cell-cycle and apoptosis effects. This practical guide connects enzyme assays, cancer research, rheumatoid arthritis research, and a septic shock murine model while separating product-backed facts from workflow recommendations.

• Salvianolic Acid B and LH2 in Pulmonary Fibrosis

  2026-08-16

  The reference study identifies lysyl hydroxylase 2 (LH2/PLOD2)-associated collagen cross-linking as a modifiable feature of pulmonary fibrosis and presents Salvianolic acid B (Dan Shen Suan B) as an inhibitor of LH2 expression. Using cell-based, molecular, and tissue-level analyses, the authors connect Salvianolic acid B treatment with reduced fibrotic remodeling, while also defining important limits for interpretation and translation.

• A 83-01: ALK-5 Inhibitor Workflow Guide

  2026-08-15

  A 83-01 enables controlled TGF-β pathway inhibition across reporter assays, EMT models, organoids, and stem-cell differentiation workflows. This guide connects dose planning and formulation with the reference study’s practical comparison of trophoblast protocols, while highlighting controls and troubleshooting steps for reproducible results.

• EV-Transferred ACLY Drives TAM Formation in HCC

  2026-08-14

  The Advanced Science study identifies extracellular vesicle transfer of ATP-citrate lyase as a direct metabolic signal that converts monocytes into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. Its CD81-targeted liposomal models establish a causal link between ACLY-driven palmitate production, immune-checkpoint protein stability, tumor progression, and improved anti-PD-1/PD-L1 responses.

• Vorinostat Workflow for Cancer Biology Research

  2026-08-14

  Build a reproducible Vorinostat workflow that connects HDAC target engagement with chromatin remodeling, cell-cycle arrest, and intrinsic apoptosis. The guide also shows how to benchmark responses across lymphoma and neuroblastoma models while avoiding common solvent, timing, and assay-normalization errors.

• Azithromycin and Roxithromycin as Senolytics

  2026-08-13

  Ozsvari et al. used DNA-damage-induced human fibroblast senescence to identify azithromycin and roxithromycin as selective senolytic candidates, while the closely related erythromycin lacked comparable activity. The study combines protein-content, real-time impedance, and metabolic analyses, providing a useful framework for drug repurposing and orthogonal senescent cell detection.

6854 records 1/457 page Next 12345 下5页 Last page